Exploring the underlying mechanisms of Ashitaba in the management of non-alcoholic fatty liver disease by integrating the analysis of transcriptomics and metabolomics

Huan Yang; Huan Yang; Huan Yang; Yunshan Li; Weihong Xu; Wenjuan Liu; Ying Xie

doi:10.3389/fmed.2023.1247851

Frontiers in Medicine (Oct 2023)

Exploring the underlying mechanisms of Ashitaba in the management of non-alcoholic fatty liver disease by integrating the analysis of transcriptomics and metabolomics

Huan Yang,
Huan Yang,
Huan Yang,
Yunshan Li,
Weihong Xu,
Wenjuan Liu,
Ying Xie

Affiliations

Huan Yang: Department of Endocrinology, The Second Affiliated Hospital of Soochow University, Suzhou, China
Huan Yang: Department of Internal Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Huan Yang: Changning Administration Center of Public Hospital and Community Healthcare Center, Shanghai, China
Yunshan Li: Department of Endocrinology, Seven People’s Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
Weihong Xu: Department of Clinical Laboratory, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Wenjuan Liu: Department of Internal Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Ying Xie: Department of Endocrinology, The Second Affiliated Hospital of Soochow University, Suzhou, China

DOI: https://doi.org/10.3389/fmed.2023.1247851
Journal volume & issue: Vol. 10

Abstract

Read online

Ashitaba seems to improve glucose intolerance and decrease triglyceride (TG) and total cholesterol (TC), which contribute to the development of non-alcoholic fatty liver disease (NAFLD). However, it remains to be explored the mechanism of Ashitaba in managing NAFLD. We determined the impact of Ashitaba on NAFLD, particularly its underlying mechanisms at the bioinformatic level. The established NAFLD mouse model was treated with or without Ashitaba, and the underlying mechanism was explored using transcriptomics paired with metabolomics. Ashitaba reduced obesity and liver steatosis in NAFLD mice. It identified 429 differentially expressed genes (DEGs) and verified 45 differential metabolites, especially those that alleviate NAFLD via the FXR signaling pathway. Our data may provide insight into the therapeutic impact of Ashitaba in the management of NAFLD and may be useful in clinical interventions for NAFLD.

Published in Frontiers in Medicine

ISSN: 2296-858X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Medicine (General)
Website: http://www.frontiersin.org/journals/medicine

About the journal

Abstract

Keywords